Skip to content
10-K

Annual Report

VITRO BIOPHARMA, INC.

0001493152-25-003942

← back to feed
Filed
Jan 28, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Jan 28, 2025 4.46M sh
Shares Diluted FY 2024 · Oct 31, 2023 4.43M sh
Capex FY 2024 · Oct 31, 2023 $121.5K
Operating Cash Flow FY 2024 · Oct 31, 2023 −$1.97M
Long Term Debt FY 2024 · Oct 31, 2023 $2.95M
Short Term Debt FY 2024 · Oct 31, 2023 $480K
Current Liabilities FY 2024 · Oct 31, 2023 $4.85M
Total Liabilities FY 2024 · Oct 31, 2023 $9.43M
Current Assets FY 2024 · Oct 31, 2023 $3.18M
Total Assets FY 2024 · Oct 31, 2023 $8.34M
Eps Diluted FY 2024 · Oct 31, 2023 −$1.21
Eps Basic FY 2024 · Oct 31, 2023 −$1.21
Sga Expense FY 2024 · Oct 31, 2023 $6.06M
Rd Expense FY 2024 · Oct 31, 2023 $206.41K
Net Income FY 2024 · Oct 31, 2023 −$5.36M
Operating Income FY 2024 · Oct 31, 2023 −$5.38M
Gross Profit FY 2024 · Oct 31, 2023 $1.47M
Cost Of Revenue FY 2024 · Oct 31, 2023 $298.05K
Revenue FY 2024 · Oct 31, 2023 $1.76M
Stockholders Equity FY 2024 · Oct 31, 2022 $2.84M